Clinical Trial Update: Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of BI-2536 in combination with pemetrexed for previously treated non-small-cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BI-2536
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: COMPLETED